Seres Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.35	-	-	-	144.93	33.22
Revenue Growth (YoY)	-	-	-	-	336.33%	-3.74%
Cost of Revenue	14.5	14.53	19.34	13.43	141.89	90.57
Gross Profit	-14.15	-14.53	-19.34	-13.43	3.04	-57.36
Selling, General & Admin	44.08	53.18	77.5	70.26	69.26	30.78
Research & Development	45.2	53.6	98.26	96.22	-	-
Other Operating Expenses	-	-	-	-	-1.73	-
Operating Expenses	89.28	106.79	175.76	166.49	67.53	30.78
Operating Income	-103.43	-121.32	-195.1	-179.91	-64.49	-88.13
Interest Expense	-	-	-2.47	-6.02	-2.91	-2.92
Interest & Investment Income	2.22	3.97	7.3	3.06	2.87	0.95
Other Non Operating Income (Expenses)	44.73	9.29	-0.1	-0.02	-0.55	1.43
EBT Excluding Unusual Items	-56.48	-108.06	-190.37	-182.89	-65.08	-88.68
Gain (Loss) on Sale of Investments	-	-	0.24	-0.69	-0.5	-0.45
Gain (Loss) on Sale of Assets	85.27	5.68	-	-	-	-
Other Unusual Items	-23.4	-23.4	-	-	-	-
Pretax Income	5.39	-125.77	-190.13	-183.58	-65.58	-89.13
Earnings From Continuing Operations	5.39	-125.77	-190.13	-183.58	-65.58	-89.13
Earnings From Discontinued Operations	-	125.91	76.41	-66.58	-	-
Net Income	5.39	0.14	-113.72	-250.16	-65.58	-89.13
Net Income to Common	5.39	0.14	-113.72	-250.16	-65.58	-89.13
Shares Outstanding (Basic)	9	8	6	5	5	4
Shares Outstanding (Diluted)	9	8	6	5	5	4
Shares Change (YoY)	19.92%	21.40%	18.44%	17.86%	14.93%	40.85%
EPS (Basic)	0.62	0.02	-17.77	-46.29	-14.30	-22.34
EPS (Diluted)	0.62	0.02	-17.77	-46.29	-14.30	-22.34
Free Cash Flow	-23.37	-148.99	-125.33	-238.64	-2.88	-94.2
Free Cash Flow Per Share	-2.69	-19.18	-19.58	-44.16	-0.63	-23.61
Gross Margin	-	-	-	-	2.10%	-172.68%
Operating Margin	-29466.95%	-	-	-	-44.50%	-265.33%
Profit Margin	1536.75%	-	-	-	-45.25%	-268.33%
Free Cash Flow Margin	-6657.55%	-	-	-	-1.99%	-283.61%
EBITDA	-99.17	-115.85	-188.85	-173.29	-58.55	-81.55
EBITDA Margin	-	-	-	-	-40.40%	-245.53%
D&A For EBITDA	4.26	5.47	6.24	6.63	5.95	6.58
EBIT	-103.43	-121.32	-195.1	-179.91	-64.49	-88.13
EBIT Margin	-	-	-	-	-44.50%	-265.33%
Revenue as Reported	0.35	-	-	-	144.93	33.22

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q